Impact Biomedical (IBO) Change in Account Payables (2022 - 2026)
Impact Biomedical's (IBO) quarterly Change in Account Payables came in at $27000.0 in Q1 2026, up 127.55% YoY from $11865.5 in Q1 2025, and down 95.55% on a QoQ basis from $607000.0 in Q4 2025.
Impact Biomedical (IBO) Change in Account Payables (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Change in Account Payables data on file, last reported at $27000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 127.55% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $595000.0 (up 182.07% YoY) and the FY2025 annual result came in at $470000.0, up 207.8% from the prior year.
- Change in Account Payables fell to $27000.0 in Q1 2026, from $607000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $607000.0 in Q4 2025 to a low of -$605000.0 in Q4 2024.
- A 5-year average of $52266.7 and a median of $22000.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables soared 369.23% — and 2024, when it tumbled 269.94%.
- Tracing IBO's Change in Account Payables over 5 years: stood at $495000.0 in 2022, then decreased by 28.08% to $356000.0 in 2023, then plunged by 269.94% to -$605000.0 in 2024, then jumped by 200.33% to $607000.0 in 2025, then plunged by 95.55% to $27000.0 in 2026.
- The last three Change in Account Payables figures came in at $27000.0 (Q1 2026), $607000.0 (Q4 2025), and $22000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93,000.00 |
| Jun 30, 2026 | 93,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 607,000.00 |
| Dec 31, 2025 | 607,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | -61,000.00 |
| Jun 30, 2025 | -61,000.00 |
| Mar 31, 2025 | -98,000.00 |
| Mar 31, 2025 | -98,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | -37,000.00 |
| Jun 30, 2024 | -37,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Mar 31, 2024 | 191,000.00 |